Prefilled insulin device with reduced injection force: patient perception and accuracy

Authors:

Abstract
Objective: The injection force and the patient perception of the Next Generation FlexPen (NGFP) with design modifications aimed at reducing injection force was assessed. The accuracy and precision of the NGFP was also tested under standard conditions. * FlexPen is a registered trade name of Novo Nordisk A/S, Bagsværd, DenmarkResearch design and methods: Dosing accuracy was tested (according to ISO 11608 requirements) at 1 IU, 30 IU and 60 IU doses (acceptable limits were 1 ± 1 IU (0–2 IU), 30 ± 1.5 IU (28.5–31.5 IU), and 60 ± 3 IU (57–63 IU)). Pens were tested at reference conditions (18–28°C and relative humidity 25–75%). Delivered doses were measured on a sensitive balance and corrected for the specific density of the insulin aspart used (according to ISO 11608-1). Precision was calculated from the variance around the mean delivered dose. The injection force of NGFP was measured, and user-preference of NGFP and FlexPen (FP) were compared in 50 patients with type 2 diabetes.Results: The mean inje...

This publication has 18 references indexed in Scilit: